I. Introduction Crohn's Disease

In the United States, it is estimated that 3 million individuals (1.3% of the adult population) suffer from IBD. [Feuerstein, 2017] About half a million of them are estimated to have Crohn's disease with symptoms including diarrhea, abdominal pain, rectal bleeding, fever, weight loss, and fatigue. [Veauthier, 2018] Most people with Crohn's are diagnosed before turning thirty. For those living with this challenging condition, finding effective treatments is crucial as it can lead to colorectal cancer with a cumulative incidence of 2% after 30 years of follow-up. [Selinger, 2014] Recently, the U.S. Food and Drug Administration (FDA) approved a groundbreaking oral medication called Upadacitinib (upadacitinib) for adults with moderately to severely active Crohn's disease. [CDER, 2023] Let's explore what makes Upadacitinib a game-changer in the management of this debilitating condition.

II. Understanding Crohn's Disease

Crohn's disease causes inflammation in the digestive tract, affecting various parts of the gastrointestinal system. Common symptoms include diarrhea, abdominal pain, cramping, weight loss, and fatigue. [Veauthier, 2018] The inflammation can lead to complications such as strictures, fistulas, and malnutrition. Until now, treatment options primarily involved injectable medications or surgery.

III. Previous treatment options

Anti-Inflammatory Drugs: Sulfasalazine, [Choi, 2024] Mesalamine, [Nakashima, 2024] and Olsalazine [Olsalazine, 2024]: These medications help reduce inflammation in the digestive tract. They are particularly effective for mild to moderate cases of Crohn's disease.

Immunosuppressants: Azathioprine [Qian, 2018] and Tacrolimus [Amine, 2018]: These drugs suppress the immune system's response, which can help manage inflammation and prevent flare-ups.

Biologics: Infliximab, [Poggioli, 2007] Adalimumab, [Bickston, 2013] and Certolizumab [Schreiber, 2011]: These are monoclonal antibodies that target specific proteins involved in inflammation. Biologics are administered via injection and are effective for moderate to severe Crohn's disease.

Antibiotics: Ampicillin, Cefotaxime, Ciprofloxacin, and Tetracycline: [Patterson, 2021] Antibiotics are used to control infections and manage symptoms. They are especially helpful for treating complications like abscesses or fistulas.

Anti-Diarrheal Agents: Loperamide [Van Outryve, 1995]: This medication helps regulate bowel movements and reduces diarrhea.

Nutritional Supplements: Ensuring proper nutrition is crucial for managing Crohn's disease. Supplements may include vitamins [WebMD, 2024] (such as vitamin B12, vitamin D, and calcium) and minerals.

Self-Care and Lifestyle Modifications: Dietary Changes: Some individuals find relief by avoiding trigger foods (such as spicy or high-fiber foods) and opting for a low-residue diet. Staying well-hydrated is essential.

IV. The Arrival of Upadacitinib

Upadacitinib represents a significant advancement in Crohn's disease management. It is the first approved oral product specifically designed to treat moderately to severely active Crohn's disease. [CDER, 2023] This means patients no longer need to rely solely on injections or infusions.

V. How Upadacitinib Works

Upadacitinib belongs to a class of medications called Janus kinase (JAK) inhibitors. [Upadacitinib, 2024] It works by targeting specific proteins within the body that contribute to inflammation. By inhibiting these proteins, Upadacitinib helps reduce the inflammatory response in the digestive tract, alleviating Crohn's symptoms.

Clinical Efficacy

The FDA evaluated Upadacitinib's efficacy and safety through rigorous clinical trials. In two randomized induction trials, patients with moderately to severely active Crohn's disease received either Upadacitinib or a placebo for 12 weeks. [CDER, 2023] The results were promising:

1. Clinical Remission: A greater proportion of patients treated with Upadacitinib achieved clinical remission based on the Crohn's Disease Activity Index (CDAI). This index measures disease activity, including clinical and laboratory variables.

2. Intestinal Inflammation Improvement: Patients treated with Upadacitinib also demonstrated improvement in intestinal inflammation, as assessed by colonoscopy.

To assess Upadacitinib's effectiveness as a maintenance treatment, another trial evaluated patients who responded well to the initial 12-week induction period. These patients continued with Upadacitinib for an additional 52 weeks. Again, Upadacitinib outperformed the placebo group in achieving clinical remission and reducing intestinal inflammation. [CDER, 2023]

Dosage and Safety

Patients typically start with a daily dose of 45 mg of Upadacitinib for 12 weeks. After the induction period, the recommended maintenance dosage is 15 mg once a day. For patients with refractory, severe, or extensive Crohn's disease, a maintenance dosage of 30 mg once daily can be considered. [CDER, 2023]

Common side effects of Upadacitinib include upper respiratory tract infections, anemia, fever, acne, herpes zoster, and headaches. It is essential to discuss any potential risks and benefits with your healthcare provider. [CDER, 2023]

VI. Finally A Pill for Crohn's Patients

Upadacitinib's approval marks a significant milestone in Crohn's disease management. Its oral formulation provides convenience and flexibility for patients, allowing them to take control of their treatment. Oral formulations of medications are often preferred over intravenous (IV) formulations for several compelling reasons. [Chionh, 2017] First and foremost, oral administration is more comfortable and less invasive for patients. Swallowing a pill or capsule is far less distressing than having a needle inserted into a vein. Additionally, oral medications eliminate the risk of bloodstream infections associated with IV lines. Patients can take their prescribed drugs at home without the need for specialized medical equipment or constant monitoring by healthcare professionals. This convenience enhances patient compliance and overall well-being. [Chionh, 2017]

Furthermore, oral formulations contribute to resource efficiency in healthcare settings. IV administration demands significant nursing resources, including monitoring the infusion process and addressing complications. By opting for oral medications, healthcare providers can allocate their time more effectively, ensuring better patient care. Additionally, oral drugs generate less waste compared to IV setups, which involve single-use plastic bags, tubing, and needles. From an environmental perspective, oral formulations are a greener choice. In summary, while IV medications remain crucial in specific situations, such as emergencies or when oral administration is not feasible, the preference for oral formulations stems from safety, comfort, reduced infection risk, resource efficiency, and cost-effectiveness . [Chionh, 2017]

VII. Conclusion

The management of Crohn's disease has witnessed a transformative breakthrough with the introduction of Upadacitinib, an oral medication approved by the U.S. Food and Drug Administration (FDA). This approval marks a significant departure from traditional treatment options, which often involved injectable medications or surgery. Upadacitinib, a Janus kinase (JAK) inhibitor, targets specific proteins contributing to inflammation in the digestive tract, providing an effective alternative for individuals with moderately to severely active Crohn's disease. Clinical trials have demonstrated its efficacy in inducing and maintaining clinical remission, as well as reducing intestinal inflammation. The shift from injection-based therapies to an oral formulation enhances patient convenience, compliance, and overall well-being, while also contributing to resource efficiency in healthcare settings. Despite potential side effects, the approval of Upadacitinib signifies a milestone in Crohn's disease management, offering a promising avenue for improved patient outcomes and quality of life.

VIII. Sources

Amine, Leena, et al. "Tacrolimus for Induction Therapy in Active Crohn's Disease." Cochrane Database of Systematic Reviews, no. 10, 2018, doi:10.1002/14651858.CD013142.

Bickston, Stephen; Asgharpour, Amon; Cheng, Jianfeng. "Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial." Clinical and Experimental Gastroenterology, vol. 7, no. 1, 2013, pp. 153. DOI: 10.2147/CEG.S35163.

CDER. "FDA Approves First Oral Treatment for Moderately to Severely Active Crohn's Disease." FDA, 18 May 2023, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-moderately-severely-active-crohns-disease.

Choi, Jaehwa, and Ardy Fenando. "Sulfasalazine." StatPearls, StatPearls Publishing, 2024, http://www.ncbi.nlm.nih.gov/books/NBK557809/.

Chionh, F., et al. "Oral versus intravenous chemotherapy for colorectal cancer." Cochrane, 2017, https://www.cochrane.org/CD008398/COLOCA_oral-versus-intravenous-chemotherapy-colorectal-cancer.

Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clin Proc. 2017;92(7):1088-1103. https://doi.org/10.1016/j.mayocp.2017.04.010.

Nakashima, Justyn, and Charles V. Preuss. "Mesalamine (USAN)." StatPearls, StatPearls Publishing, 2024, http://www.ncbi.nlm.nih.gov/books/NBK551714/.

"Olsalazine - an overview | ScienceDirect Topics." ScienceDirect, https://www.sciencedirect.com/topics/neuroscience/olsalazine. Accessed 28 Feb. 2024.

Patterson, Joshua. "Effectiveness of Antibiotics as a Treatment Option for Patients with Crohn's Disease: A Meta Analysis." Gastroenterology, vol. 3, no. 160, 2021, S9. DOI: 10.1053/j.gastro.2021.01.052.

Poggioli, Gilberto, et al. "Infliximab in the Treatment of Crohn's Disease." Therapeutics and Clinical Risk Management, vol. 3, no. 2, 2007, pp. 301-308. Dove Press, doi:10.2147/tcrm.2007.3.2.301.

Qian, Xiaoxian, et al. "Low Dose of Azathioprine Is Effective to Induce and Maintain Remission in Active Crohn Disease: A Prospective Observational Study." Medicine, vol. 97, no. 34, 2018, e11814, https://journals.lww.com/00005792-201808240-00021. doi:10.1097/MD.0000000000011814.

Schreiber, Stefan. "Certolizumab pegol for the treatment of Crohn's disease." Therapeutic Advances in Gastroenterology, vol. 6, no. 4, 2011, pp. 375-389. DOI: 10.1177/1756283X11413315.

Selinger, Christian P., et al. "Long-term Follow-up Reveals Low Incidence of Colorectal Cancer, but Frequent Need for Resection, Among Australian Patients With Inflammatory Bowel Disease." Clinical Gastroenterology and Hepatology, vol. 12, no. 4, 2014, pp. 644-650, doi:10.1016/j.cgh.2013.05.017.

"Upadacitinib." DrugBank, https://go.drugbank.com/drugs/DB15091. Accessed 29 Feb. 2024.

Van Outryve, M, and J Toussaint. "Loperamide Oxide for the Treatment of Chronic Diarrhoea in Crohn's Disease." Journal of International Medical Research, vol. 23, no. 5, 1995, pp. 335-341. DOI: 10.1177/030006059502300503.

Veauthier, Brian, and Jaime R. Hornecker. "Crohn's Disease: Diagnosis and Management." American Family Physician, vol. 98, no. 11, 2018, pp. 661-669. Doi:10.1532-0650.

WebMD Editorial. "Vitamins for Crohn's Disease." WebMD, WebMD, https://www.webmd.com/ibd-crohns-disease/crohns-disease/crohns-vitamins. Accessed 29 Feb. 2024.

About the Author:

David Orchard-Webb

David Orchard-Webb, Ph.D., is a technical writer with broad interests including health & technology writing, plus extensive training and knowledge of biomedicine and microbiology. My Ph.D. and postdoc were in oncology and developing cancer medicines. I provide technical medical and other writing services for projects ranging from “knowledge automation” to pure pharma, to food safety, to the history of science, and everything in between. I also provide white papers, ebooks, meta-analysis reviews, editing, consulting, business, and market research-related activities in biomedicine, technology, and health. In addition to its well-known role in the development of medicines, I am a big believer in biotechnology’s ability to revolutionize industries such as food-tech, agtech, textiles & fashion.